PROLEUKIN
Drug
CLINIGEN, INC.
Total Payments
$13.9M
Transactions
58
Doctors
21
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $7.4M | 20 | 0 |
| 2022 | $6.5M | 37 | 20 |
| 2019 | $31.25 | 1 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $13.9M | 37 | 100.0% |
| Food and Beverage | $3,022 | 20 | 0.0% |
| Consulting Fee | $480.00 | 1 | 0.0% |
Payments by Type
Research
$13.9M
37 transactions
General
$3,502
21 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| PHASE II TRIAL OF DAILY LD IL-2 | CLINIGEN, INC. | $1.5M | 0 |
| PHASE I TRIAL OF REGULATORY T-CELLS PLUS LD IL-2 FOR STEROID-REFRACTORY CGVHD | CLINIGEN, INC. | $1.4M | 0 |
| LOW DOSE SUB CUTANEOUS IL-2 IN CROHNS DISEASE | CLINIGEN, INC. | $1.2M | 0 |
| CD40L-AUGMENTED (TIL) FOR ONCOGENE-DRIVEN ADVANCED NSCLC | CLINIGEN, INC. | $1.1M | 0 |
| 3 IITS TIL | CLINIGEN, INC. | $1.1M | 0 |
| MELANOMA AND RENAL CELL CARCINOMA | Clinigen, Inc. | $1.0M | 0 |
| 5 TIL TRIALS WITH HD IL-2 IN MULTIPLE TUMORS | CLINIGEN, INC. | $966,367 | 0 |
| LYMPHODEPLETION +ACT WITHOUT DENDRITIC CELL IMMUNIZATION | CLINIGEN, INC. | $894,404 | 0 |
| PHASE II TRIAL OF COMBINATION ANTI-PD-1 AND ALDESLEUKIN FOR METASTATIC | Clinigen, Inc. | $771,038 | 0 |
| PHASE II TRIAL OF LD IL-2 ADDED TO EXTRA-CORPOREAL PHOTOPHERESIS FOR STEROID-REFRACTORY CGVHD | CLINIGEN, INC. | $648,083 | 0 |
| ADOPTIVE CELL THERAPY IN SELECTED CD39CD103 T CELLS IN MM AND SCHN | CLINIGEN, INC. | $582,904 | 0 |
| HD IL-2 IN COMBINATION WITH PEMBRO MM AND RCC | CLINIGEN, INC. | $555,147 | 0 |
| TILFOLLOWING IL-2 IN METASTATIC MELANOMA | CLINIGEN, INC. | $555,147 | 0 |
| NEOANTIGEN TCRT | CLINIGEN, INC. | $340,490 | 0 |
| A BIOMARKER STUDY OF LOW-DOSE IL-2 + PEMBRO | CLINIGEN, INC. | $166,544 | 0 |
| PHASE IB TRIAL INTRAPERITONEAL IL-2 AND PD-1 INHIBITION IN GASTRIC CANCER | CLINIGEN, INC. | $166,544 | 0 |
| T CELL RECEPTOR GENE THERAPY TARGETINGKK-LC-1 CANCERS | Clinigen, Inc. | $166,544 | 0 |
| SINGLE PT IND- TGFB RESIS TIL + IPI AND NIVO IN PT W PERITONEAL CA | CLINIGEN, INC. | $164,488 | 0 |
| TIL INTRAVESICAL ADMIN NMIBC | CLINIGEN, INC. | $133,235 | 0 |
| T-CELL RECEPTOR GENE THERAPY TARGETING MUTANT KRAS IN PANCREATIC CANCER. SINGLE PATIENT IND FOR 2 PTS- REPEAT INFUSIONS X 1 PT | CLINIGEN, INC. | $123,366 | 0 |
Top Doctors Receiving Payments for PROLEUKIN
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Potomac, MD | $13.9M | 37 |
| , M.D | Specialist | New York, NY | $480.00 | 1 |
| , MD | Internal Medicine | Santa Monica, CA | $157.40 | 1 |
| , MD | Medical Oncology | Portland, OR | $157.40 | 1 |
| , MD | Neurology | Tampa, FL | $157.40 | 1 |
| , MD | Hematology & Oncology | Buffalo, NY | $157.40 | 1 |
| , MD | Medical Oncology | Chicago, IL | $157.40 | 1 |
| , MD | Internal Medicine | Indianapolis, IN | $157.40 | 1 |
| , MD | Medical Oncology | New Haven, CT | $157.40 | 1 |
| , MD | Internal Medicine | Charlotte, NC | $157.40 | 1 |
| , M.D | Medical Oncology | Boston, MA | $157.40 | 1 |
| , M.D | Medical Oncology | Boston, MA | $157.40 | 1 |
| , MD PHD | Medical Oncology | New Haven, CT | $157.40 | 1 |
| , M.D | Clinical Genetics (M.D.) | Washington, DC | $157.40 | 1 |
| , MD | Medical Oncology | Seattle, WA | $157.40 | 1 |
| , MD MBBS | Medical Oncology | Buffalo, NY | $157.40 | 1 |
| , M.D., PH.D | Hematology & Oncology | Columbus, OH | $157.40 | 1 |
| , M.D., PH.D | Medical Oncology | Tampa, FL | $157.40 | 1 |
| , MD | Specialist | Pittsburgh, PA | $157.40 | 1 |
| , MD | Medical Oncology | New Haven, CT | $157.40 | 1 |
| , MD | Hematology & Oncology | Boston, MA | $157.40 | 1 |
| , M.D | Pediatric Hematology-Oncology | Gainesville, FL | $31.25 | 1 |
Ad
Manufacturing Companies
- CLINIGEN, INC. $11.8M
- Clinigen, Inc. $2.1M
- Novartis Pharmaceuticals Corporation $31.25
Product Information
- Type Drug
- Total Payments $13.9M
- Total Doctors 21
- Transactions 58
About PROLEUKIN
PROLEUKIN is a drug associated with $13.9M in payments to 21 healthcare providers, recorded across 58 transactions in the CMS Open Payments database. The primary manufacturer is CLINIGEN, INC..
Payment data is available from 2019 to 2023. In 2023, $7.4M was paid across 20 transactions to 0 doctors.
The most common payment nature for PROLEUKIN is "Unspecified" ($13.9M, 100.0% of total).
PROLEUKIN is associated with 20 research studies, including "PHASE II TRIAL OF DAILY LD IL-2" ($1.5M).